GlassScriptPhysician profile
Aaron Buzard
NPI 1487036158
$496.47
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.98 · 2020: $63.98 · 2021: $349 · 2022: $25.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $132.78 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.66 | 2020-2021 | |
| Glaxosmithkline, LLC. | $64.26 | 2021-2022 | |
| Novo Nordisk INC | $38.57 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $29.82 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.00 | 2021 | |
| Amgen INC. | $25.19 | 2019 | |
| Amarin Pharma, INC. | $18.61 | 2019 | |
| Dexcom, INC. | $15.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.72 | 2021 | |
| Mylan Specialty L.P. | $13.81 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.62 | 2021 | |
| Lilly USA, LLC | $13.03 | 2021 | |
| Abbvie INC. | $12.77 | 2022 | |
| Apria Healthcare LLC | $11.84 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Buzard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.